RayKnowChina Research Map
Shortlist0

Xiamen University

厦门大学

XiamenUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
1.3%Leads about 1 in 76 of China's research papers on NPC ▲ from 0.3%

Led 31 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
5
Research papers it led
31
Trials it led
6
Share of China's trials
1.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025
ThemesInduction / concurrent chemotherapyRadiotherapy techniqueRecurrent / metastatic disease

Hospitals counted here

  1. First Affiliated Hospital of Xiamen University27
  2. Zhongshan Hospital, Xiamen University Counted in the group total2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Risk Stratification in T4 or N3 Nasopharyngeal Carcinoma.2026Cancer research and treatmentFree full text
  2. Real-world treatment practices and survival outcomes of patients with de novo metastatic nasopharyngeal carcinoma after chemoimmunotherapy.2025Cancer immunology, immunotherapy : CIIFree full text
  3. Two or three cycles of induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma?2025BMC cancerFree full text
  4. Induction Camrelizumab and Modified TPF (Nab-Paclitaxel, Cisplatin, and S-1) in Locoregionally Advanced Nasopharyngeal Carcinoma.2025Cancer scienceFree full text
  5. Nasopharyngeal carcinoma survival by histology in endemic and non-endemic areas.2024Annals of medicineFree full text
Trials on ClinicalTrials.gov6
  1. Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal CarcinomaRecruitingNCT07137052Lead sponsorStart 2025-08
  2. Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPCRecruitingNCT07085234Lead sponsorPhase 2Start 2025-07
  3. Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPCRecruitingNCT06811844Lead sponsorPhase 2Start 2025-02
  4. IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal CarcinomaEnrolling by invitationNCT06688175Lead sponsorPhase 2Start 2024-11
  5. SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of ImmunotherapyRecruitingNCT06676722Lead sponsorPhase 2Start 2024-11
  6. Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07064902Study sitePhase 2Start 2026-08

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.5%Leads under 1 in 100 of China's research papers on ESCC

Led 16 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
16
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesNeoadjuvant & combined treatmentImmunotherapySurgery

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Xiang'an Hospital, Xiamen University7
  2. First Affiliated Hospital of Xiamen University7
  3. Zhongshan Hospital, Xiamen University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Comparison of efficacy and safety in two versus three cycles of neoadjuvant immunotherapy plus chemotherapy for esophageal squamous cell carcinoma.2025Journal of cardiothoracic surgeryFree full text
  2. Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery is related to unimproved pathological response and poor survival prognosis for esophageal squamous cell carcinoma.2025BMC gastroenterologyFree full text
  3. Potential biomarkers develop for predicting the prognosis of patients with esophageal squamous cell carcinoma after optimized chemoradiotherapy using serum metabolomics.2025BMC cancerFree full text
  4. Metastatic patterns of subcarinal, right and left recurrent laryngeal nerve lymph nodes in thoracic esophageal squamous cell carcinoma without neoadjuvant therapy.2024Journal of cancer research and clinical oncologyFree full text
  5. Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and 2024International journal of surgery (London, England)Free full text
Trials on ClinicalTrials.gov6
  1. A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)RecruitingNCT07405151Study sitePhase 1/Phase 2Start 2026-03
  2. Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingNCT06780111Study sitePhase 1/Phase 2Start 2025-07
  3. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  4. A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingNCT05319730Study sitePhase 1/Phase 2Start 2023-05
  5. To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCCStatus unknownNCT05818982Study sitePhase 2Start 2023-02
  6. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCStatus unknownNCT05221658Study sitePhase 2Start 2022-08

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.5%Leads under 1 in 100 of China's research papers on HCC

Led 73 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
2
Research papers it led
73
Trials it led
3
Share of China's trials
0.2%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Zhongshan Hospital, Xiamen University27
  2. First Affiliated Hospital of Xiamen University21
  3. Xiang'an Hospital, Xiamen University Counted in the group total10
  4. Second Hospital of Fuzhou Affiliated Xiamen University1
  5. Xiang'an Hospital Counted in the group total1
  6. Chenggong Hospital, Xiamen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Analysis of different prognoses in two hepatocellular carcinoma patients with pathological complete response after conversion therapy: a case report.2025Journal of medical case reportsFree full text
  2. Case Report: Long-term disease-free survival in an advanced hepatocellular carcinoma patient: an exceptional response to PD-1 inhibitor therapy.2025Frontiers in immunologyFree full text
  3. Comparing neoadjuvant targeted therapy plus transarterial chemoembolization versus triple therapy including immunotherapy in hepatocellular carcinoma: a Chinese multicentre study.2025Cancer immunology, immunotherapy : CIIFree full text
  4. Preoperative prediction of microvascular invasion and relapse-free survival in hepatocellular Carcinoma ≥3 cm using CT radiomics: Development and external validation.2025BMC medical imagingFree full text
  5. Hepatocellular Carcinoma with Multiple Primary Malignancies: A Retrospective Study of 106 Cases.2025Oncology
Trials on ClinicalTrials.gov6
  1. GPC3-Targeted PET/CT in Hepatocellular CarcinomaRecruitingNCT07677774Lead sponsorN/AStart 2026-05
  2. Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular CarcinomaRecruitingNCT05970666Lead sponsorPhase 2Start 2023-11
  3. Neoadjuvant Triple Therapy for Resectable HCCRecruitingNCT06569498Study siteStart 2024-09
  4. Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)RecruitingNCT06602011Study siteStart 2024-09
  5. Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular CarcinomaStatus unknownNCT01924624Lead sponsorN/AStart 2013-07
  6. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.7%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 72 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
1
Research papers it led
72
Trials it led
6
Share of China's trials
0.4%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesNutrition & recoveryImmunotherapy & targeted drugsPeritoneal spread & advanced disease

Hospitals counted here

  1. First Affiliated Hospital of Xiamen University31
  2. Zhongshan Hospital, Xiamen University30
  3. Xiang'an Hospital, Xiamen University Counted in the group total2
  4. Southeast Hospital, Xiamen University1
  5. Oriental Hospital, Xiamen University1
  6. Successful Hospital, Xiamen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study.2025Advances in therapyRCTFree full text
  2. Early vs conventional initiation of adjuvant chemotherapy in advanced gastric cancer: A propensity-matched outcomes study.2025World journal of gastroenterologyFree full text
  3. An Epidemiological Study on Survival in Lymphoma of Mucosa-Associated Lymphoid Tissue: A Comparative Analysis by Primary Tumor Location.2025Journal of investigative surgery : the official journal of the Academy of Surgical Research
  4. Endoscopic resection for gastric subepithelial tumours: a retrospective cohort study.2025Annals of medicineFree full text
  5. Clinical outcomes of double-flap technique versus gastric tube reconstruction following laparoscopic proximal gastrectomy: a multicenter propensity score-matched cohort study.2025World journal of surgical oncologyFree full text
Trials on ClinicalTrials.gov6
  1. A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06415669Lead sponsorPhase 2Start 2024-05
  2. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  3. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  4. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  5. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  6. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.7%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 16 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
16
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
0.8%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour ▲ from 0.3%

Led 4 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. Children's Hospital, Xiamen University2
  2. First Affiliated Hospital of Xiamen University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.4%Leads under 1 in 100 of China's research papers on Neuroblastoma New since 2021

Led 5 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Xiangan Hospital, Xiamen University2
  2. Zhongshan Hospital, Xiamen University1
  3. Xiang'an Hospital1
  4. Xiang'an Hospital, Xiamen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.7%Leads under 1 in 100 of China's research papers on Myeloma

Led 12 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
2
Research papers it led
12
Trials it led
2
Share of China's trials
0.4%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 442025
ThemesKidney & bone complicationsDrug combinationsDiagnosis, MRD & risk

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Xiamen University7
  2. Zhongshan Hospital, Xiamen University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Secondary myeloma in patients with chronic lymphoblastic leukemia: A case report and analysis of data from SEER database.2021Current problems in cancer
  2. LAMP5 modulates IRF4 stability and nuclear transport: a critical mechanism in myeloma progression and therapy.2025OncogeneFree full text
  3. Chemotherapy-Mediated Induction of PD-L1 via SEI1 Facilitates Myeloma Immune Evasion.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction.2025Nature communicationsFree full text
  5. Novel insights into the circ_0003489/let-7b-5p/GLUT1 axis and its possible role in multiple myeloma.2025Transplant immunology
Trials on ClinicalTrials.gov6
  1. Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT06581640Lead sponsorPhase 2Start 2024-09
  2. All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple MyelomaRecruitingNCT06158412Lead sponsorPhase 2Start 2023-11
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  4. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10
  5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  6. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.0%Leads none of China's research papers on B-ALL

Led 0 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
0.6%Leads under 1 in 100 of China's research papers on Beta thalassaemia New since 2021

Led 2 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Zhongshan Hospital, Xiamen University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.5%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis New since 2021

Led 5 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 2220242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Xiang'an Hospital, Xiamen University2
  2. First Affiliated Hospital of Xiamen University2
  3. Zhongshan Hospital, Xiamen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.4%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis New since 2021

Led 3 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Xiamen University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
0.9%Leads under 1 in 100 of China's research papers on Duchenne muscular dystrophy New since 2021

Led 2 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.08%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Xiamen University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
1.1%Leads about 1 in 92 of China's research papers on IgA nephropathy New since 2021

Led 8 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025

Hospitals counted here

  1. Zhongshan Hospital, Xiamen University5
  2. First Affiliated Hospital of Xiamen University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
2.0%Leads about 1 in 50 of China's research papers on Osteogenesis imperfecta New since 2021

Led 2 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Children's Hospital, Xiamen University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症
1.8%Leads about 1 in 56 of China's research papers on Inherited epidermolysis bullosa ▼ from 7.1%

Led 1 of 56 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.5%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

PubMed searchClinicalTrials.gov